Modafinil for the Treatment of Alcohol Use Disorders

NCT ID: NCT03424681

Last Updated: 2020-05-26

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-12-11
• Study Completion Date: 2018-08-31

Brief Summary

Alcohol use disorder (AUD) is a major cause of morbidity and mortality and more treatments are needed, especially pharmacotherapies. There are a variety of efficacious treatments for AUD, but effect sizes are small, and vary from study to study. Medications may be more effective if particular subgroups of AUD are targeted. Identifying the mechanisms of action of a particular medication will help identify the subtypes more likely to respond to therapy. Global impulse control is a rational treatment target, and improving it is a likely mechanisms by which some medications for AUD work, especially in subtypes of AUD with impaired impulse control at baseline. Modafinil is a medication that is FDA approved for the treatment of narcolepsy, and is relatively safe and tolerable. There is reason to believe it may improve impulse control, and underlying neural circuitry, and may work best to improve alcohol use outcomes in AUD with poor impulse control. The overall aim of this study is to investigate the effects of modafinil on task performance and the integrity of neural circuits mediating response inhibition in treatment-seeking AUD with poor response inhibition, to establish target engagement. Secondary aims are to measure whether target engagement mediates improvement in alcohol use outcomes, and to utilize machine learning to identify neural and behavioral markers which best predict treatment outcomes. Twenty-four individuals with AUD and impaired response inhibition will be enrolled in the study, randomized to modafinil or placebo, and treated for 6 weeks. Functional magnetic resonance imaging brain scans during a response inhibition task and during rest will be obtained at baseline and 2 weeks. Aversive stimuli will be included in the response inhibition task to assure that efficacy generalizes to several conditions. Diffusion imaging and arterial spin labeling sequences will also be obtained. Investigators predict that modafinil will significantly increase brain activity in the medial and lateral prefrontal cortex during response inhibition, thereby establishing target engagement, and that it will improve alcohol use outcomes. Findings will provide information about whether or not a larger R01 trial investigating the efficacy of modafinil for individuals with AUD and impaired response inhibition is warranted.

Detailed Description

see above.

Conditions

Alcohol Use Disorder

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Modafinil

Modafinil 300 mg by mouth each day

Group Type: EXPERIMENTAL

Modafinil

Intervention Type: DRUG

Modafinil 300 mg by mouth daily

Placebo

Identical looking capsule/number of capsules by mouth each day without active medication

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Placebo

Interventions

Modafinil

Modafinil 300 mg by mouth daily

Intervention Type: DRUG

Placebo

Placebo

Intervention Type: OTHER

Other Intervention Names

Provigil

Eligibility Criteria

Inclusion Criteria

• Males and females age 18-65 meeting Diagnostic and Statistical Manual V criteria for moderate or severe AUD in the past year
• Interested in cutting down or quitting
• Able to provide voluntary informed consent
• Have at least 4 heavy drinking days (≥ 5 drinks per day for men, and 4 for women) in the past 60 days
• Stop signal reaction time on a stop signal task>233

Exclusion Criteria

• Severe neurological conditions (severe traumatic brain injury/stroke/active seizure disorder)
• Heart disease [mitral valve prolapse, left ventricular hypertrophy, cardiac arrhythmias, angina, myocardial infarction, unstable angina, cardiac syncope or pre-syncope, any electrocardiogram (ECG) finding that suggests the presence of one of these conditions]
• Uncontrolled hypertension (systolic blood pressure >160, diastolic blood pressure >100)
• Heart rate greater than 70% of the maximum expected for age [0.70(220-age)]
• Chronic renal or hepatic failure
• Recent pancreatitis
• Insulin-dependent diabetes
• Other urgent medical problems
• Elevated liver function tests (AST or ALT greater than 4 times normal; modafinil is metabolized primarily by the liver)
• Schizophrenia, schizoaffective disorder, Bipolar I disorder, suicidal thoughts in the last month
• Current moderate or severe other substance use disorder (SUD) (except nicotine or marijuana)
• Active legal problems with the potential to result in incarceration
• Pregnancy or lactation, or child bearing age and not on birth control
• Current daily use of anti-craving medications, stimulants, benzodiazepines, opiates, anti-psychotics; current daily use of tricyclic antidepressants, bupropion, monoamine oxidase inhibitors, serotonin and norepinephrine reuptake inhibitors, or therapeutic doses (for bipolar disorder) of mood stabilizers
• Taking a medication contraindicated for use with modafinil

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

The Mind Research Network

OTHER

Sponsor Role: lead

Responsible Party

Claire Wilcox

Associate Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Claire Wilcox, MD

Role: PRINCIPAL_INVESTIGATOR

Mind Research Network

Locations

Mind Research Network

Albuquerque, New Mexico, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

FP00002746

Identifier Type: -

Identifier Source: org_study_id